Leukemia’s Management in Developing Countries

Leukemia, a group of hematological malignancies characterized by abnormal proliferation of white blood cells, poses a significant health challenge worldwide, including in developing countries. This chapter provides a comprehensive overview of the prevalence, morbidity, and mortality of leukemia in developing countries, along with its clinical, economic, and humanistic burden. It explores the causes, risk factors, and complications associated with leukemia, emphasizing the challenges faced by healthcare systems in resource-constrained settings. The clinical presentation, diagnosis, and management strategies, including non-pharmacological and pharmacological interventions, are discussed. The chapter highlights the importance of monitoring parameters, evaluating therapeutic outcomes, and addressing modifiable risk factors. While leukemia management in developing countries has achieved notable successes in raising awareness, improving diagnostic capabilities, and expanding access to treatment, challenges remain, such as limited resources, high treatment costs, and late diagnoses. To address these challenges, the chapter recommends a wide array of strategies, including telemedicine, patient navigation, patient and family support programs, and collaborations with international organizations and pharmaceutical companies. It emphasizes the need for government commitment, data collection, and healthcare workforce training. In addition to these recommendations, the chapter underscores the importance of preventive measures, such as vaccination and infection control, to reduce the incidence of leukemia. It also highlights the significance of reducing diagnostic delays, addressing the psychosocial needs of patients, and supporting leukemia survivors in their long-term care journey. In conclusion, this chapter provides a comprehensive and actionable roadmap for improving leukemia management in developing countries. By implementing these recommendations and fostering collaboration among stakeholders, we can work toward reducing the burden of leukemia, improving patient outcomes, and ensuring equitable access to quality care in these regions.